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Abstract
TRPV1, a cation channel on sensory nerves sensitive to heat and capsaicin, plays an important role
in the transduction of noxious stimuli to the spinal cord. It is expressed by neurons in dorsal root
ganglia (DRG) that may also express neuropeptides, which are important for the development of
inflammation. Mice with genetic deletion of TRPV1 have been used to study the involvement of this
receptor in the mediation of pain and inflammation in animal models of arthritis. However, the
expression of TRPV1 in the mouse articular afferents has not been studied. We here provide
numerical data on expression of TRPV1 in an identified population of sensory afferents to the mouse
L3–L5 DRG that innervate joints, in comparison with that from bladder and skin. A combination of
tracing and immunocytochemistry revealed that TRPV1-positive fibers innervate the mouse knee
and ankle. At the level of DRG, ~40% of articular afferents from these joints express TRPV1 and
the majority of them are peptidergic, as revealed by simultaneous immunostaining for the
neuropeptide calcitonin gene-related peptide. These findings are consistent with the idea that
activation of TRPV1 in peripheral axons of joint afferents may mediate the synovial release of
neuropeptides in arthritis.
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1. Introduction
An important step for our understanding of nociception was the cloning of the receptor for
capsaicin (the pungent ingredient in hot peppers), the vanilloid receptor TRPV1. TRPV1 is a
non-selective cation channel expressed by many neurons in dorsal root ganglia (DRG, Caterina
et al., 1997) and in their peripheral processes in skin and viscera (Tominaga et al., 1998) and
central processes in the spinal and trigeminal dorsal horn (Guo et al., 1999).
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TRPV1 in the skin is important for thermal nociception and inflammatory hyperalgesia and
allodynia, and has also been implicated in neuropathic pain (Hudson et al., 2001). In vitro,
TRPV1-expressing cells can be activated by protons (pH<6) or heat (>43°C) as well as by
vanilloids, like capsaicin. Mice lacking the TRPV1 gene do not respond to vanilloids and have
reduced sensitivity to noxious heat and low pH, indicating that TRPV1 contributes to heat and
proton sensitivity in vivo (Caterina et al., 2000; Karai et al., 2004). In mice, knocking out the
TRPV1 gene prevented thermal hyperalgesia in an experimental model of hindpaw
inflammation (Caterina et al., 2000; Davis et al., 2000), and capsazepine (a selective TRPV1
antagonist) prevented the development of mechanical hyperalgesia in experimental
inflammation (Walker et al., 2003).
Besides the skin, TRPV1-positive sensory afferents innervate many deep structures of the body
(Robinson et al., 2004; Ward et al., 2003); moreover, the fraction of DRG neurons that express
TRPV1 is much higher for visceral and muscle afferents than for cutaneous afferents
(Christianson et al., 2006a; Hwang et al., 2005a; Zhong et al., 2008). The presence of TRPV1
in joints was proposed based on the articular effects of capsaicin, to which it is the only known
receptor (Holzer, 1991). More recently, the expression of TRPV1 in articular afferents has been
suggested by immunostaining of nerve fibers within the rat temporomandibular joint (Ichikawa
et al., 2004; Ioi et al., 2006) and rat and human knee joints (Fernihough et al., 2005).
TRPV1-KO mice provide an excellent negative control for studies of the involvement of
capsaicin-sensitive sensory afferents in several models of painful inflammatory conditions,
including arthritis (Bolcskei et al., 2005). The severity of adjuvant-induced arthritis of the knee
(Barton et al., 2006; Keeble et al., 2005) and ankle (Szabo et al., 2005) was found to be
significantly reduced in TRPV1-KO mice. However, the expression of TRPV1 in mouse
articular afferents has not been studied. It is also unclear what is the relationship between the
articular afferents that express TRPV1 and those that could release the neuropeptide calcitonin
gene-related peptide (CGRP), an important mediator of pain and inflammation in arthritis
(Schaible et al., 2002). CGRP has been shown in rat articular afferents at the level of DRG
(O'Brien et al., 1989) and the knee joint (Schwab et al., 1997) and the release of CGRP into
the joint was found to be increased in experimental arthritis in rats (Ahmed et al., 1995). CGRP-
KO mice have reduced behavioral pain responses in experimental arthritis, consistent with a
pro-nociceptive role for CGRP in joints (Zhang et al., 2001). The reported increase in
expression of both TRPV1 and CGRP in a rat model of arthritis has been controversial
(Fernihough et al., 2005; Staton et al., 2007) and data on colocalization of the two markers in
mouse articular afferents is lacking.
Thus, further anatomical characterization of the TRPV1-positive afferents from joints is needed
to better understand the organization of articular nociceptive pathways. The goal of the present
study was to ascertain whether TRPV1 is expressed by articular afferents in the mouse, to
provide basic numerical data on the fraction of TRPV1-positive articular afferents, in
comparison with afferents of cutaneous and visceral origin to the same DRG, and to determine
what fraction of them is peptidergic. For this, we use a combination of tracing and
immunocytochemistry and show that TRPV1-positive afferents innervate knee and ankle joints
in the mouse and that the majority of them co-express CGRP.
2. Results
In sections of joints, many nerve fibers were strongly immunoreactive for TRPV1 in the
periosteum of periarticular bone and within the articular capsule; most TRPV1-positive fibers
were also stained for CGRP (Fig. 1). TRPV1-positive fibers were frequently associated with
the vasculature of the articular capsule and were often within the vessel wall of larger vessels;
virtually all fibers innervating larger blood vessels were double-stained (Fig. 1C). Few fibers
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were single-stained for PGP9.5, a generic marker for all peripheral nerve fibers, suggesting
that the majority of nerve fibers innervating joint tissues are TRPV1-positive (Fig. 1D,E).
Specifically, numerous nerve fibers had varicose appearance with immunostaining for TRPV1
concentrating in beads along the fiber. However, some small bundles or individual thin fibers
on the surface of the femur and tibia, apparently innervating the periosteum, were
immunostained for CGRP but not for TRPV1.
Three days after the tracer injections, multiple DRG neurons were labeled with FB on the side
of the injection; bladder injections produced bilateral labeling. Most labeled neurons were in
L3–L4 DRG after knee injections, in L4–L5 DRG after ankle injections, and in L5 DRG after
bladder and skin injections. Double immunofluorescence revealed that many neurons
retrogradely-labeled with FB express TRPV1, CGRP, or both (Fig. 2). Cell counts revealed
that while in naïve mice ~37% of all DRG neurons expressed TRPV1 and ~ 23% expressed
CGRP, the percentages in afferents of identified sources varied according to the type, and for
joint afferents were ~44% and ~39% for TRPV1 and ~44% and ~53% for CGRP for the ankle
and the knee afferents, respectively (Table 1). In comparison, fractions for skin afferents in the
same ganglia were generally lower and for bladder afferents were generally higher: of all
identified skin and bladder afferents respectively, ~ 33% and ~58% stained for TRPV1 and ~
35% and ~69% stained for CGRP. Counts of double- and triple-labeled neurons further
revealed that 29–31% of the identified articular afferents expressed both TRPV1 and CGRP
and that 70–77% of the TRPV1-positive articular afferents expressed CGRP. These fractions
were also lower for the skin afferents (~21% and ~65%) and higher for the blabber afferents
(~54% and ~92%).
3. Discussion
We here report for the first time that i) TRPV1-positive fibers innervate the mouse knee and
ankle, ii) at the level of DRG, ~40% of articular afferents from these joints express TRPV1,
and iii) the majority of TRPV1-expressing articular afferents are peptidergic.
The expression of TRPV1 in articular afferents has been suggested by the involvement of
capsaicin-sensitive afferents in experimental arthritis (Helyes et al., 2004; Tang et al., 2004)
and supported by immunostaining of nerve fibers within the rat temporomandibular joint
(Ichikawa et al., 2004; Ioi et al., 2006) and rat and human knee joints (Fernihough et al.,
2005). Many of the TRPV1-positive fibers innervating the articular capsule in the knee and
ankle, and the posterior aspect of the patellar ligament, appeared to terminate in the sub-
synovial connective tissue as free axonal endings and displayed varicosities characteristic of
the sensory afferents described in the cat’s knee (Schaible, 1996). The CGRP-positive fiber
bundles in the periosteum, some of which were also TRPV1-positive, likely correspond to
those described as providing sensory and sympathetic innervation of the mouse femur (Mach
et al., 2002). The TRPV1-negative fibers were also likely to be of sympathetic origin (Ioi et
al., 2006). The close association of TRPV1-positive fibers with blood vessels and
colocalization with CGRP was analogous to that reported in the rat temporomandibular joint
(Ioi et al., 2006; Ishikawa et al., 2005). TRPV1 has also been demonstrated in synovial
fibroblasts from patients with arthritis, suggesting that it may play a role also in non-neuronal
mechanisms of nociception in joints (Engler et al., 2007; Kochukov et al., 2006); we were
unable to obtain convincing immunostaining of synovial cells in the mouse. TRPV1 has also
been reported to colocalize with the marker for non-peptidergic afferents IB4 in nerve fibers
in the rat temporomandibular joint (Ioi et al., 2006), but not knee (Ivanavicius et al., 2004),
consistent with the idea that the distinction between peptidergic and non-peptidergic TRPV1-
expressing afferents based on co-labeling for IB4 may be unreliable in the rat (Hwang et al.,
2005b; Price and Flores, 2007; Woodbury et al., 2004).
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We did not attempt to quantify the immunostaining for TRPV1 and CGRP in peripheral nerve
fibers in joint sections. However, while the majority of (PGP9.5-positive) nerve fibers in
sections of knees and ankles were immunolabeled for TRPV1, a much lower fraction (~40%)
of DRG neurons back-labeled from these two joints expressed TRPV1. This apparent
discrepancy may be explained if, compared to the cell body in DRG, peripheral axons of
articular afferents had higher levels of TRPV1, favoring their detection with
immunocytochemistry (Hwang and Valtschanoff, 2003). Alternatively, leakage of the tracer
during injection may have caused FB-labeled DRG cells to include neurons from unintended
sources, i.e. proprioceptive, muscle, and skin afferents in articular injections, peritoneal
afferents in bladder injections, etc. To minimize the influence of this difficult to control
variable, we injected a relatively small volume of more highly concentrated tracer (than the
standard 1%) through the thinnest available needle and included in the analysis only mice that
did not exhibit retrogradely-labeled motor neurons in the lumbar spinal cord. The tracer may
further skew the results from cell counts by favoring fibers of a particular class or from a
particular source. For example, the tracers wheat-germ agglutinin (WGA) and cholera toxin B
(CTB) may label preferentially unmyelinated and myelinated afferents, respectively; however,
while this selectivity may apply to afferents of somatic origin (labeled with tracer injections
into the sciatic nerve, Valtschanoff et al., 1994), the opposite may be true for visceral afferents
(Wang et al., 1998). We here chose FB, which does not have a known bias for a particular class
or source of afferents, to provide counts for articular, cutaneous and visceral afferents to the
same ganglion, retrogradely-labeled with the same tracer, as a basis for comparison with
previously-published data.
Our counts of identified articular afferents that immunostain for TRPV1 and the fraction that
also stain for CGRP agree with previously reported data in mice (Salo et al., 2002) and rats
(Fernihough et al., 2005; Ichikawa et al., 2004; Ochiai et al., 2007). They were higher that that
in cutaneous afferents and lower than that in visceral afferents, also consistent with previous
reports. Thus, using the same experimental strategy as the present study, Christianson et al.
(2006a) found that mouse colonic afferents (labeled with CTB) contained the highest
percentage of both TRPV1- and CGRP-positive neurons, followed by muscle afferents (labeled
with WGA) and cutaneous afferents (labeled with WGA and IB4), further supported by Zhong
et al. (2008), who reported that of identified gastric neurons in the mouse (labeled with CTB),
77% expressed TRPV1 and 82% expressed CGRP, of muscle neurons, 40% expressed TRPV1
and 39% expressed CGRP, and of skin neurons, 26% expressed TRPV1 and 18% expressed
CGRP. These data are also consistent with the previously published percentages for mouse
colonic afferents labeled with FB (82% stained for TRPV1 and 81% stained for CGRP, BALB/
c mice, Robinson et al., 2004). However, as suggested above, the value of comparing counts
of immunopositive primary afferent neurons and/or peripheral fibers across different studies
may be limited by multiple difficult to control variables, including the choice of tracer, the
strain, age, and gender of the animal, the neuronal segment level, the immunohistochemical
protocol, the specific criteria for counting, etc. For example, thoraco-lumbar DRG contained
significantly higher percentage of TRPV1-and CGRP-positive colonic afferents than lumbo-
sacral DRG in mice but not in rats (Christianson et al., 2006b), the degree of colocalization of
TRPV1 and CGRP in peripheral afferent axons varied with the particular viscus within the
gastrointestinal tract (Ward et al., 2003), and even our counts in naïve mice differed
significantly from those of Zwick et al. (2002), who reported that out of all afferents in the
mouse lumbar DRG, 22% expressed TRPV1 and 30% expressed CGRP and those of Robinson
et al. (2004), who reported that 42% of all DRG afferents immunostained for TRPV1 and 27%
immunostained for CGRP. Yet, the vagaries of the method notwithstanding, our results
establish baseline values that can be useful in interpreting the results of experiments based on
mouse models of arthritis.
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Discussion of the functional importance for TRPV1 has so far been primarily focused on its
thermoreceptive role in the skin. That TRPV1 may also play a role in joints and viscera is
suggested by its ubiquitous expression in nerve fibers in various deep structures of the body
and by the effects of capsaicin on internal organs of experimental animals and humans (Ballet
et al., 2003). Since sensory nerves in joints and viscera are not normally exposed to high heat
or capsaicin, however, the functional role of TRPV1 in non-cutaneous afferents remains
elusive. TRPV1 in articular afferents may be a target for endogenously-released ligands (Di
Marzo et al., 2002) or function as a proton detector (Christianson et al., 2006a). It may also
contribute directly to the pathogenesis of arthritis by mediating the release of neuropeptides
from nerve fibers in joints. In support of such mechanism, studies suggest that activation of
TRPV1 may trigger peripheral release of neuropeptides (McVey and Vigna, 2001; Nathan et
al., 2001) and that peptidergic afferents in joints may release neuropeptides into the synovial
fluid in the course of arthritis (Lotz et al., 1987; Saito and Koshino, 2000). That TRPV1 is
expressed by peptidergic nerve fibers in joints is consistent with the possibility that synovial
release of neuropeptides during inflammation is triggered by depolarization of these fibers via
TRPV1. The issue could be addressed by a functional study using knockout mice or antagonists
of TRPV1.
4. Experimental procedures
Twelve male C57/BL6J mice (25–35g; Jackson Laboratories, Bar Harbor, ME) were used in
this study. All experimental procedures involving mice were carried out in compliance with
the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals,
according to a protocol approved by the Institutional Animal Care and Use Committee at UNC.
To label articular afferents and to compare the fraction that are TRPV1 and/or CGRP-positive
to that of identified cutaneous and visceral afferents to the same DRG, mice anesthetized with
a mixture of ketamine and xylazine (90 mg/kg and 10 mg/kg, i.p.) were injected with 0.5 µl of
the axonal tracer Fast Blue (FB, 2% aqueous solution containing 5% DMSO; EMS-Chemie
GmbH), using a 30-gauge needle attached to a Hamilton syringe. Mice received a single
injection into the knee (n=3) or ankle (n=3) joint on one side and the skin on the posterior side
of the thigh on the other side (four sites ~ 1 mm apart), or the wall of urinary bladder (four
sites ~ 1 mm apart, n=3), exposed through a lower median laparotomy under asepsis. DRGs
of mice that did not receive any injections (n=3) were used to study expression of TRPV1 and
CGRP in naïve mice.
Three days after tracer injections, the mice were re-anaesthetized with sodium pentobarbital
(80 mg/kg, i.p.) and perfused intracardially with 30 ml heparinized saline, followed by 100 ml
freshly prepared solution of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB).
Tissues, including the L3–L5 DRG bilaterally, and joint preparations of ankles and knees that
were not injected with FB, were dissected out, postfixed in 4% paraformaldehyde for 4 hrs,
and stored in PB. Joint preparations were decalcified in Rapid Cal Immuno (BBC Biochemical
through Fisher Scientific, Pittsburgh, PA) for 3 days. Tissue blocks were further cryoprotected
in 30% sucrose in PB for 24–48 hrs and sectioned on a cryostat at 20 µm, and sections were
collected on slides and stored at −20°C.
All incubations for fluorescent immunohistochemistry were carried out on a shaker at room
temperature. Sections were permeabilized with 50% ethanol in phosphate-buffered saline
(PBS; 0.01 M, pH 7.4) for 30 min, blocked with 10% normal donkey serum (NDS; Jackson
Immunoresearch, West Grove, PA) in PBS, and incubated overnight with a mixture of two or
three primary antibodies in PBS: goat anti-TRPV1 (Cat# SC12498, Santa Cruz Biotechnology,
Santa Cruz, CA; 1:1,000), rabbit anti-CGRP (Cat# AB5920, Chemicon, Temecula, CA;
1:2,000), and guinea pig anti-PGP9.5 (Cat# 14104, Neuromics, Minneapolis, MN; 1:500).
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After several rinses with PBS and incubation with 2% NDS for 30 min, sections were incubated
with appropriate secondary antibodies (fluorescein isothiocyanate-, Cy3-, or Cy5-conjugated
antibodies raised in donkey, 1:200; Jackson Immunoresearch). Finally, sections were rinsed,
mounted on slides and coverslipped with Vectashield (Vector, Burlingame, CA).
The antibodies used in this study are well characterized and are in common use in our
laboratory. As a matter of routine control, sections were processed according to the above
protocols, except that primary or secondary antibodies were omitted, or blocking peptides were
added at concentrations recommended by the suppliers. Omission of primary or secondary
antibodies or preadsorption with blocking peptides completely abolished specific staining.
Joint sections were examined on a laser confocal microscope (SP2, Leica, Wetzlar, Germany);
since laser illumination with a wavelength appropriate for visualization of FB-labeled cells
was unavailable on the confocal microscope, images of DRG sections were acquired with a
Retiga EX cooled CCD camera (QImaging, Burnaby, Canada) attached to a Leitz DMR
fluorescent microscope (Leitz, Wetzlar, Germany) at 10X, and saved as TIFF files using
OpenLab software (Improvision, Lexington, MA). Brightness and contrast were adjusted with
Photoshop CS2 (Adobe Systems, San Jose, CA); all enhancements were applied to the entire
image. Some images of joint sections immunostained for TRPV1 were acquired with a
conventional fluorescent microscope (Leitz DMR/Retiga EX) and used for Fig. 1.
To quantify colocalization of FB, TRPV1, and CGRP in DRG neurons, neuronal profiles were
counted in 4–8 sections per ganglion at 80 µm intervals in each of L3–L5 DRG in each mouse
by an investigator blinded to the source material. In every section, positive neuronal profiles
were counted in one gray-scale image for each of the three fluorescent channels. Neuronal
profiles were identified by their characteristic cellular morphology. The cut-off brightness level
(labeling density threshold) was determined by averaging the integral brightness of three
neuronal profiles per image that were judged to be minimally positive using Image J 1.38x
software (NIH, Bethesda, MD); all profiles whose mean labeling density exceeded this
threshold were counted as positive. To avoid counting the same profile more than once, each
positive profile was labeled with a dot, color-coded after the respective fluorescent channel.
To determine colocalization, the three gray-scale images containing the colored dots were
overimposed and the fraction of profiles in each of the eight categories [blue, green, red, yellow
(green+red), purple (blue+red), aqua (blue+green), white (triple-labeled), and black
(unlabeled; immuno-negative neurons in naïve mice were visualized with phase-interference
contrast)] in each section were normalized to the total number of profiles and expressed as a
percentage of total counted profiles (Marvizon et al., 2002). Data were analyzed with one-way
analysis of variance (ANOVA), followed by Tukey’s post hoc test, using Kaleidagraph
(Synergy Software, Reading, PA); statistical significance was set at p<0.05.
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A, B: Fluorescent microscopy of sections through the mouse knee (A) and ankle (B)
immunostained for TRPV1; A1, A2 and B1, B2 are enlargements of the respective boxed areas
in A and B. Various joint elements are labeled to help orientation: Cart, articular cartilage of
the distal epiphysis of the femur (A) and the tibia and talus (B); Syn, synovial layer of the
articular capsule; CT, connective tissue layer of the articular capsule. TRPV1-immunopositive
nerve fivers in the subsynovial tissues are pointed to with arrows. C–E: Confocal microscopy
of triple immunofluorescent staining for TRPV1, CGRP, and the marker for peripheral nerve
fibers PGP9.5 in sections through mouse ankle (C, D) and knee (E) joints. C: Some fibers that
stain simultaneously for TRPV1 and CGRP (arrows, the staining for PGP9.5 is not shown for
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clarity) are apparently associated with small blood vessels (asterisks), while others appear to
terminate as free nerve fibers (arrowheads). D, E: Colocalization of TRPV1 with CGRP is
apparent in varicosities (beads) along the nerve fibers (arrows). Scale bars = 20 µm, except for
A, B=100 µm.
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Triple immunofluorescence for the axonal tracer FB (blue), TRPV1 (red), and CGRP (green)
in sections of mouse lumbar DRG (tracer injection sites and DRG segments are indicated on
the bottom). Intraarticular injections of FB label afferent neurons that innervate joints, many
of which co-immunostain for TRPV1 and CGRP (solid arrows; examples of articular afferents
that immunostain for either TRPV1 or CGRP alone are pointed to with open arrows). Scale
bars = 50 µm.
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Table 1
Expression of TRPV1 in identified sensory afferents and colocalization with CGRP
Afferents TRPV1 CGRP Double TRPV1 also CGRP
Ankle (228) 43.5±4.9 44.3±4.0 30.7±5.1 70.1±6.0
Knee (140) 39.0±2.8 52.6±3.7 28.5±3.0 77.1±11.2
Skin (911) 32.5±1.5 35.3±1.4 21.1±1.5 64.8±4.4
Bladder (604) 58.2±1.9 68.7±3.4 53.7±1.3 92.3±1.5
Naïve (1379) 36.7±1.8 23.3±2.0 28.3±0.9 64.4±1.2
Counts of DRG neuronal profiles, labeled after injections of the tracer FB in the ankle, knee, skin or bladder that express TRPV1, CGRP, or both (Double,
“TRPV1 also CGRP” is the fraction of TRPV1 neurons that also express CGRP); the total number of profiles counted for each type of afferents are given
in parentheses. Values are percentages (mean±SEM) of total FB-labeled profiles, or of all profiles in naïve mice. Counts were not significantly different
between animals within a group and were pooled from 4–8 sections in each of L3–L5 DRG per animal in 3 mice for each type of afferents, double-stained
for TRPV1 and CGRP as in Fig. 2.
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